|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00241488 |
This clinical trial is being performed to investigate the effect of 12 weeks treatment with rosuvastatin and atorvastatin in bringing subjects to their established EAS LDL-C target goal.
Condition | Intervention | Phase |
Hypercholesterolemia |
Drug: Rosuvastatin |
Phase III |
Genetics Home Reference related topics: | hypercholesterolemia |
MedlinePlus related topics: | Cholesterol |
ChemIDplus related topics: | Atorvastatin Atorvastatin calcium Rosuvastatin Rosuvastatin calcium |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | : An Open-Label, Randomised, Multi-Centre, Phase IIIb/IV, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia (DISCOVERY) |
Estimated Enrollment: | 1362 |
Study Start Date: | June 2003 |
Study Completion Date: | February 2007 |
Primary Completion Date: | December 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Visit 1:
Subjects willing to follow all study procedures including attendance at clinics for scheduled study visits, fasting prior to blood draws and compliance with study treatment regimen
Visit 2:
Exclusion Criteria:
China | |||||
Shanghai, China | |||||
nanjing, China | |||||
Beijing, China | |||||
Harbin, China | |||||
Wu Han, China | |||||
Guang Zhou, China | |||||
Ji Nan, China | |||||
Shenyang, China | |||||
Ching Qing, China | |||||
Hong Kong | |||||
New Territories, Hong Kong | |||||
Korea, Republic of | |||||
Seoul, Korea, Republic of | |||||
Daegu, Korea, Republic of | |||||
Cheonan-si, Korea, Republic of | |||||
Wonju, Korea, Republic of | |||||
Pusan, Korea, Republic of | |||||
Suwon, Korea, Republic of | |||||
Busan, Korea, Republic of | |||||
Ilsan, Korea, Republic of | |||||
Incheon-Si, Korea, Republic of | |||||
Kwangju, Korea, Republic of | |||||
Pyungchon Kyonggi, Korea, Republic of | |||||
Malaysia | |||||
Kuala Lumpur, Malaysia | |||||
Petaling Jaya, Malaysia | |||||
Seberang Perai Utara, Malaysia | |||||
Penang, Malaysia | |||||
Malaysia, Sarawak | |||||
Kuching, Sarawak, Malaysia | |||||
Malaysia, Selangor | |||||
Bandar Sunway, Selangor, Malaysia | |||||
Shah Alam, Selangor, Malaysia | |||||
Taiwan | |||||
Taipei, Taiwan | |||||
Taichung City, Taiwan | |||||
Kaohsiung, Taiwan | |||||
Tao-Yuan, Taiwan | |||||
Chunghua City, Taiwan | |||||
Thailand | |||||
Bangkok, Thailand |
AstraZeneca |
Study Director: | AstraZeneca China Medical Director, MD | AstraZeneca |
Study ID Numbers: | D3560L00009, D3560L00009, DISCOVERY-Asia |
First Received: | October 18, 2005 |
Last Updated: | February 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00241488 |
Health Authority: | China: Ministry of Health |
|
|
|
|